Previous 10 | Next 10 |
NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement to acquire the residual royalty interest in Vertex Pharmaceuticals, Inc.’s cystic fibrosis (CF) treatments owned by the Cystic Fibrosis Foundation. The agreement includes an upf...
NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today the closing of the secondary offering of 17,343,037 shares of its Class A ordinary shares by selling shareholders in an underwritten public offering at a price to the ...
NEW YORK, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX) today announced that it will report its third quarter 2020 financial results on Wednesday, November 11, 2020 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at ...
Royalty Pharma (RPRX) announced pricing of secondary offering by selling shareholders of 17.3M Class A ordinary shares at $42 per share.Expected to grant the underwriters an option to purchase up to 2.6M additional shares.The company will not receive any of the proceeds from th...
NEW YORK, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today the pricing of the secondary offering of 17,343,037 shares of its Class A ordinary shares by selling shareholders in an underwritten public offering pursuant to a regi...
Royalty Pharma (RPRX) declares $0.15/share quarterly dividend, in line with previous.Forward yield 1.4%Payable Dec. 15; for shareholders of record Nov. 20; ex-div Nov. 19.See RPRX Dividend Scorecard, Yield Chart, & Dividend Growth. For further details see: Royalty Pharma declares $0...
NEW YORK, Oct. 15, 2020 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2020 of $0.15 per class A share. The dividend will be paid on December 15, 2020, to shareholders of record at the cl...
Royalty Pharma (RPRX) -3.3% AH, announced today that certain selling shareholders intend to offer 17.3M of the company's Class A ordinary shares in an underwritten public offering.Expected to grant the underwriters an option to purchase up to 2.6M additional shares.The company will ...
NEW YORK, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today that certain selling shareholders intend to offer an aggregate 17,343,037 of the Company's Class A ordinary shares in an underwritten public offering. The selling shar...
New Ventures Funds Rebrands as Scientia Ventures PR Newswire NEW YORK, Oct. 2, 2020 NEW YORK , Oct. 2, 2020 /PRNewswire/ -- New Ventures Funds has launched a new corporate brand identity and changed its name to Scientia Ventures. The new website for the firm ...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experie...
2024-07-24 08:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 ...